Back to Search
Start Over
319O ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC.
- Source :
-
Annals of Oncology . Nov2022 Suppl 9, Vol. 33, pS1564-S1564. 1p. - Publication Year :
- 2022
- Subjects :
- *CRIZOTINIB
*NON-small-cell lung carcinoma
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 33
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 160398256
- Full Text :
- https://doi.org/10.1016/j.annonc.2022.10.356